Market Place
Sourcing Support
AnaptysBio Ends Eczema Drug Development After Trial Failure
11 Dec 2024 //
REUTERS
Anaptys scraps atopic dermatitis asset after ph. 2 fail
10 Dec 2024 //
FIERCE BIOTECH
Anaptys Announces Participation in Nov & Dec Investor Conferences
05 Nov 2024 //
GLOBENEWSWIRE
Anaptys Announces Q3 2024 Financial Results & Business Update
05 Nov 2024 //
GLOBENEWSWIRE
Anaptys Announces Participation in September Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Anaptys Announces Pricing Of $100 Million Direct Offering
14 Aug 2024 //
GLOBENEWSWIRE
Anaptys Reports Q2 2024 Results And Business Update
05 Aug 2024 //
GLOBENEWSWIRE
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
10 May 2024 //
ENDPTS
Anaptys Gets $50M For More Jemperli Royalties From Sagard Deal
09 May 2024 //
GLOBENEWSWIRE
Anaptys Positive Imsidolimab Phase 3 Results In Pustular Psoriasis
09 May 2024 //
GLOBENEWSWIRE
Anaptys Announces Q1 2024 Financials And Business Update
09 May 2024 //
GLOBENEWSWIRE
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results
11 Mar 2024 //
GLOBENEWSWIRE
Anaptys to Present at TD Cowen™s 44th Annual Health Care Conference
29 Feb 2024 //
GLOBENEWSWIRE
Anaptys to Present at Guggenheim™s 6th Annual Biotechnology Conference
31 Jan 2024 //
GLOBENEWSWIRE
Anaptys picks up rival to Biogen autoimmune asset from Centessa
28 Nov 2023 //
FIERCE BIOTECH
Anaptys Expands Immune Cell Modulator Pipeline
27 Nov 2023 //
GLOBENEWSWIRE
Anaptys Named a BioSpace 2024 Best Places to Work Winner
07 Nov 2023 //
GLOBENEWSWIRE
Anaptys Announces Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
Anaptys Announces Participation in November Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Anaptys to Present Phase 1 Data on ANB032
11 Oct 2023 //
GLOBENEWSWIRE
Chasing Boehringer, Anaptys hits goal in skin disease phase 3
10 Oct 2023 //
FIERCE BIOTECH
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist
09 Oct 2023 //
GLOBENEWSWIRE
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board
18 Sep 2023 //
GLOBENEWSWIRE
AnaptysBio to Present at Stifel 2023 Immunology and Inflammation Virtual Summit
12 Sep 2023 //
GLOBENEWSWIRE
AnaptysBio Announces Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
AnaptysBio Announces Participation in Upcoming Investor Conferences
30 May 2023 //
GLOBENEWSWIRE
AnaptysBio Announces First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab
02 May 2023 //
GLOBENEWSWIRE
AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors
06 Apr 2023 //
GLOBENEWSWIRE
AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results
01 Mar 2023 //
GLOBENEWSWIRE
AnaptysBio to Participate at Cowen & Company 43rd Annual Health Care Conference
27 Feb 2023 //
GLOBENEWSWIRE
AnaptysBio Announces Stock Repurchase Plan
13 Jan 2023 //
GLOBENEWSWIRE
AnaptysBio Announces Portfolio Update Across Immune Cell Modulating Antibodies
05 Jan 2023 //
PRESS RELEASE
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
21 Nov 2022 //
GLOBENEWSWIRE
AnaptysBio to Participate in Upcoming November Investor Conferences
09 Nov 2022 //
GLOBENEWSWIRE
AnaptysBio Announces3Q 2022 Financial Results and Provides Pipeline Update
08 Nov 2022 //
GLOBENEWSWIRE
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly)
05 Oct 2022 //
GLOBENEWSWIRE
AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million
12 Sep 2022 //
GLOBENEWSWIRE
AnaptysBio looks to punt IL-36 drug — even as PhIII goes on
01 Sep 2022 //
ENDPTS
AnaptysBio Reports HARP Phase 2 Top-Line Data Imsidolimab
31 Aug 2022 //
PRESS RELEASE
AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab
31 Aug 2022 //
GLOBENEWSWIRE
AnaptysBio Announces Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
AnaptysBio to Participate at 2022 Wedbush PacGrow Healthcare Virtual Conference
05 Aug 2022 //
GLOBENEWSWIRE
Chasing Lilly, MiroBio raises $97M for autoimmune checkpoint R&D
28 Jun 2022 //
FIERCEBIOTECH
AnaptysBio to Participate at the 2022 Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
AnaptysBio Announces Q1 2022 Financial Results
04 May 2022 //
GLOBENEWSWIRE
AnaptysBio Announces Positive ANB032 Top-Line Phase 1 Data
27 Apr 2022 //
GLOBENEWSWIRE
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
21 Mar 2022 //
GLOBENEWSWIRE
AnaptysBio`s ACORN fails, marking end of acne program
16 Mar 2022 //
FIERCEBIOTECH
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data
14 Mar 2022 //
GLOBENEWSWIRE
AnaptysBio says Q4 and FY 2021 Financial Results
07 Mar 2022 //
GLOBENEWSWIRE
AnaptysBio Announces Appointment of Daniel Faga to Board of Directors
29 Nov 2021 //
GLOBENEWSWIRE
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
15 Nov 2021 //
GLOBENEWSWIRE
AnaptysBio To Present at the 2021 Jefferies London Healthcare Conference
15 Nov 2021 //
GLOBENEWSWIRE
Sagard bags $250M cash deal for royalties
27 Oct 2021 //
ENDPTS
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties $250 M
25 Oct 2021 //
GLOBENEWSWIRE
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial
02 Oct 2021 //
GLOBENEWSWIRE
AnaptysBio Up 10% on GSK Drug Indication Approval
17 Aug 2021 //
MARKETWATCH
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly)
17 Aug 2021 //
YAHOO
